Trial reportOpen forum infectious diseases2026
The Use of Step-Down Oral Antibiotic Therapy for Uncomplicated Gram-Negative Bacteremia and Risk Factors for Adverse Outcomes.
Trial report in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Step-down oral antibiotic therapy (SDO) is commonly used to treat uncomplicated gram-negative bacteremia (GNB), but real-world treatment outcomes and risk factors for failure remain unclear. Methods: We conducted a retrospective cohort study of hospitalized adults with uncomplicated GNB within a large integrated healthcare system from 2018 to 2022, stratifying patients by antibiotic route: complete course of intravenous antibiotic (CIV) or initial intravenous followed by SDO. The primary outcome was a composite of 90-day all-cause mortality, all-cause readmission, or recurrent GNB. Secondary analysis identified risk factors for adverse outcomes using multivariable Cox regression. Results: We included 9164 patients, of whom 8263 received SDO and 901 received CIV therapy. All-cause mortality was 1.1% overall, with no significant difference between groups (CIV 1.4% vs SDO 1.0%, Conclusions: Step-down oral antibiotic therapy appears as effective as CIV for treating uncomplicated GNB, with comparable mortality. A high CCI score is a strong predictor of adverse outcomes. Fluoroquinolones remain a favorable SDO option, though further research is warranted to evaluate alternative oral antibiotic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.